Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hengrui Out-licenses Ex-China Rights to Asthma/Sinusitis Therapy in $1 Billion Deal

publication date: Aug 16, 2023

Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. SHR-1905 is an anti-TSLP monoclonal antibody aimed at severe asthma. One Bio will make an $21.5 million payment upfront along with a $3.5 million milestone. Hengrui said it would be eligible for over $1 billion in milestones if the drug is approved in the US, Japan and European countries, plus double-digit royalties. Hengrui has started China Phase II trials of the candidate for asthma and chronic sinusitis. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital